This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

PROMETRIKA Selects Medidata Solutions As Strategic Partner

Stock quotes in this article: MDSO

As clinical trial sponsors increase their focus on reducing costs, accelerating studies and mitigating risk, contract research organizations (CROs) continue to look to Medidata Solutions (NASDAQ: MDSO) as a leading source of clinical development technology. Boston-area based CRO PROMETRIKA recently joined the Medidata Partner Program in order to increase sponsor access to its range of clinical research solutions.

  • “CROs are under growing pressure to help sponsors make critical clinical and operational gains, which means viewing their research process holistically and delivering products and services that will enable them to reach the strategic goals for every pipeline,” said Graham Bunn, vice president of partnerships, Medidata Solutions. “Our partnership with PROMETRIKA reinforces both sponsor and CRO reliance on our technologies to transform the trial process, from concept to conclusion.”

After working with Medidata Rave on nearly 20 studies, PROMETRIKA joined Medidata’s Partner Program as a Medidata Services Partner and has committed to attain Rave accreditation in order to meet growing sponsor and site demand for Medidata Rave®, the industry’s leading electronic data capture (EDC) and clinical data management (CDM) system. With a strong focus on biostatistics and data management, as well as preparing FDA submissions, PROMETRIKA manages Phase I-IV trials across a range of therapeutic categories. In addition to Medidata’s market leadership, PROMETRIKA’s decision to partner with Medidata was also driven by Rave's standards-based approach to structured data, which allows for easy conversions of Rave-centric data into datasets for statistical analysis.

  • “Medidata clearly understands the business and operational challenges faced by our customer base – new and established biotechs that are working on some of the most innovative research in the world,” said Dr. Miganush Stepanians, president and CEO of PROMETRIKA. “We chose Medidata as a partner not only for its experience and expertise across the clinical development process, but also for its ability to help us continue to provide the most leading-edge technologies to our sponsor customers.”

Connect with Medidata:

About Medidata Solutions Worldwide

Medidata Solutions is a leading global provider of SaaS clinical development solutions that enhance the efficiency of customers’ clinical trials. Medidata’s advanced solutions lower the total cost of clinical development by optimizing clinical trials from concept to conclusion: from study and protocol design, trial planning and budgeting, site negotiation, clinical portal, trial management, randomization and trial supply management, clinical data capture and management, safety events capture, medical coding to business analytics. Our diverse life science customer base spans biopharmaceutical companies, medical device and diagnostic companies, academic and government institutions, CROs and other research organizations, and includes more than 20 of the top 25 global pharmaceutical companies as well as organizations of all sizes developing life-enhancing medical treatments and diagnostics.

About PROMETRIKA, LLC

Founded in 2003 in Cambridge, Massachusetts, PROMETRIKA, LLC, is a contract research organization that offers a full range of integrated clinical research services to its pharmaceutical and biotechnology clients, including clinical trial management, clinical monitoring, data management, biostatistics, medical writing and regulatory submissions. PROMETRIKA's team has extensive expertise and experience in managing clinical trials, analyzing and interpreting medical data, and preparing new drug applications for US and European regulatory agencies in a broad range of therapeutic areas. Collectively, the PROMETRIKA team has managed more than 300 clinical trials, ranging from Phase 1 pharmacokinetic crossover trials to Phase 4 long-term multi-center studies.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,804.71 -238.19 -1.40%
S&P 500 1,946.16 -26.13 -1.32%
NASDAQ 4,422.0850 -71.3050 -1.59%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs